Historic Milestone for Vertex and CRISPR Therapeutics Sickle Cell Therapy

Posted by ISPE Boston
On April 7, 2023

Vertex Pharmaceuticals and CRISPR Therapeutics have completed the rolling Biologics License Applications (BLAs) to the FDA for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The BLAs include requests for Priority Review, which, if granted, would shorten the FDA’s review of the application to eight months from the time of […]

Chapter Member Anniversaries: April 2023

Posted by ISPE Boston
On April 3, 2023

Please congratulate the following members celebrating milestone anniversaries in April 2023. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Ryan Ark, Alnylam Pharmaceuticals Rick Cavalli, NECI Michael Cheney, Biogen Idec Donald Cole, Hart Passivation Services, Inc. Daniel Crosby, Bristol Myers Squibb James Grunwald, DPS Group Paul Herbert, […]

Welcome New Members March 2023!

Posted by ISPE Boston
On April 3, 2023

We would like to introduce the Members who joined ISPE in March 2023, welcome them to the Chapter and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]

Scholarship Application Opens on April 3rd!

Posted by ISPE Boston
On March 28, 2023

Are you interested in pursuing a career in biotechnology and pharmaceutical manufacturing? Are you an undergrad or grad student enrolled in an accredited college or university located in New England or the Albany/Schenectady area? Are you pursuing a certification or an associate, bachelor, master or a doctoral degree in any of the STEM (Science, Technology, […]

Good News for Biogen on Two Fronts

Posted by ISPE Boston
On March 23, 2023

Biogen welcomed the VA’s recent decision to provide coverage of the company’s new Alzheimer’s drug Leqembi for veterans living with early stages of the disease. Biogen partner Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. […]

Wentworth to Build Life Sciences Complex on Huntington Ave

Posted by ISPE Boston
On March 23, 2023

Wentworth Institute of Technology has selected Huntington Development Group to build a mixed-use life science project at 500 Huntington Ave., currently site of its main athletic field. Huntington Development Group. The approximately $ billion project calls for 640,000 square feet of life science space, retail and restaurant space. Additionally, the development will include publicly accessible […]

Blue Skies & Powder at Waterville Valley!

Posted by Jim Grunwald
On March 20, 2023

On Friday March 3rd the Annual Boston Chapter Ski/Snowboard travelled to Waterville Valley for a day on the slopes! Mother Nature delivered in a big way with bluebird skies, only the occasional zephyr and a weeks’ worth of new snow delivering the best conditions of the season. Over the years, this outing has grown in […]

QurAlis Raises $88 Million for Neurodegenerative Disease Treatment

Posted by ISPE Boston
On March 16, 2023

QurAlis has closed an oversubscribed $88 million Series B financing, bringing total funds raised to $143.5 million. QurAlis is a clinical-stage biotech developing precision medicines for ALS (amyotrophic lateral sclerosis) and other neurodegenerative diseases with genetically validated targets. The financing was led by EQT Life Sciences, investing from the LSP Dementia Fund, Sanofi Ventures, and […]

Mediar Wins $105 Million Financing for Fibrosis Therapies

Posted by ISPE Boston
On March 16, 2023

Mediar Therapeutics has announced a $105M financing, including a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Bristol Myers Squibb, Eli Lilly & Company, Mass General Brigham Ventures and others. Mediar is advancing a portfolio of first-in-class therapies that halt and even reverse […]

Startup Chroma Secures $135M to Advance Epigenetic Editing Technology

Posted by ISPE Boston
On March 9, 2023

Epigenetic editing pioneer Chroma Medicine has completed a $135 million Series B financing from a syndicate of investors led by GV (Google Ventures). The financing will support advancement of Chroma’s therapeutic programs toward the clinic and continued investment in the company’s core epigenetic editing platform. “In the year since launch, we have made significant progress […]

Page 24 of 118«‹22 232425 26 ›»